TransMedics Group (NASDAQ:TMDX) Price Target Increased to $127.00 by Analysts at JPMorgan Chase & Co.

TransMedics Group (NASDAQ:TMDX) had its price objective boosted by JPMorgan Chase & Co. from $105.00 to $127.00 in a research note issued to investors on Wednesday, Benzinga reports. They currently have an overweight rating on the stock.

A number of other equities research analysts have also recently issued reports on the stock. Morgan Stanley upped their target price on shares of TransMedics Group from $75.00 to $95.00 and gave the company an equal weight rating in a report on Wednesday, February 28th. Oppenheimer lifted their target price on TransMedics Group from $105.00 to $125.00 and gave the stock an outperform rating in a research note on Wednesday. Finally, Piper Sandler restated an overweight rating and issued a $120.00 price target (up previously from $95.00) on shares of TransMedics Group in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, TransMedics Group currently has an average rating of Moderate Buy and a consensus price target of $119.00.

TransMedics Group Stock Up 2.9 %

TMDX stock opened at $127.99 on Wednesday. TransMedics Group has a twelve month low of $36.42 and a twelve month high of $129.66. The company has a market cap of $4.19 billion, a price-to-earnings ratio of -376.44 and a beta of 1.87. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69. The business has a 50 day moving average price of $85.54 and a two-hundred day moving average price of $76.85.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.40. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 8.29%. The business had revenue of $96.90 million during the quarter, compared to analysts’ expectations of $83.78 million. During the same period last year, the business earned ($0.08) earnings per share. The firm’s revenue was up 132.9% on a year-over-year basis. Analysts anticipate that TransMedics Group will post -0.14 EPS for the current fiscal year.

Insider Transactions at TransMedics Group

In other TransMedics Group news, CFO Stephen Gordon sold 15,000 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $74.01, for a total value of $1,110,150.00. Following the transaction, the chief financial officer now directly owns 23,299 shares of the company’s stock, valued at approximately $1,724,358.99. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, insider Tamer I. Khayal sold 63,260 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $108.54, for a total transaction of $6,866,240.40. Following the transaction, the insider now directly owns 9,792 shares of the company’s stock, valued at $1,062,823.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Stephen Gordon sold 15,000 shares of TransMedics Group stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $74.01, for a total transaction of $1,110,150.00. Following the completion of the sale, the chief financial officer now owns 23,299 shares of the company’s stock, valued at $1,724,358.99. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 236,378 shares of company stock worth $23,633,449. Company insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Hedge funds have recently added to or reduced their stakes in the stock. Venturi Wealth Management LLC bought a new stake in shares of TransMedics Group during the 1st quarter valued at $30,000. Fidelis Capital Partners LLC acquired a new position in TransMedics Group in the first quarter valued at about $35,000. Cutler Group LLC CA lifted its position in TransMedics Group by 600.0% during the third quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock worth $38,000 after purchasing an additional 600 shares during the period. RiverPark Advisors LLC acquired a new stake in TransMedics Group during the third quarter worth about $60,000. Finally, First Horizon Advisors Inc. increased its holdings in TransMedics Group by 26.8% in the 4th quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock valued at $83,000 after buying an additional 222 shares during the period. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.